F-group (family)
2.1.1.1 Ribosom_S12_S23
Ligands and drugs
3,507
Member domains
960
with ligand contacts (≤ 4 Å)
27.4% of members
450
with DrugDomain annotations
12.8% of members
38
with a DrugBank compound
1.1% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 2.1.1.1 belongs to X-group 2 OB-fold, which binds 7.0 ligand superclasses per 20 proteins, narrower than 59% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01082 | SRY | Streptomycin | 16 |
| DB14128 | NAD | Nadide | 15 |
| DB04626 | AM2 | Apramycin | 5 |
| DB01421 | PAR | Paromomycin | 3 |
| DB00759 | TAC | Tetracycline | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| MGmetal | MAGNESIUM ION | 833 |
| Kmetal | POTASSIUM ION | 103 |
| OHX | osmium (III) hexammine | 78 |
| NAD | NICOTINAMIDE-ADENINE-DINUCLEOTIDE | 31 |
| SRY | STREPTOMYCIN | 19 |
| UNX | UNKNOWN ATOM OR ION | 12 |
| AM2 | APRAMYCIN | 11 |
| SPM | SPERMINE | 9 |
| PAR | PAROMOMYCIN | 8 |
| 5I0 | [(2~{S},3~{S},4~{S},5~{R},6~{S})-2-[(2~{R},3~{R},4~{R},5~{S})-2-[(1~{R},2~{S},3~{R},4~{R},5~{S},6~{R})-2,4-bis[[azaniumylidene(azanyl)methyl]amino]-3,5,6-tris(oxidanyl)cyclohexyl]oxy-4-[bis(oxidanyl)methyl]-5-methyl-4-oxidanyl-oxolan-3-yl]oxy-6-(hydroxymethyl)-4,5-bis(oxidanyl)oxan-3-yl]-methyl-azanium | 3 |
| GET | GENETICIN | 2 |
| NAmetal | SODIUM ION | 2 |
| 3TS | (2S,3S,4R,5R,6R)-2-(aminomethyl)-5-azanyl-6-[(2R,3S,4R,5S)-5-[(1R,2R,3S,5R,6S)-3,5-bis(azanyl)-2-[(2S,3R,4R,5S,6R)-3-azanyl-5-[(4-chlorophenyl)methoxy]-6-(hydroxymethyl)-4-oxidanyl-oxan-2-yl]oxy-6-oxidanyl-cyclohexyl]oxy-2-(hydroxymethyl)-4-oxidanyl-oxolan-3-yl]oxy-oxane-3,4-diol | 1 |
| 84D | Dibekacin | 1 |
| LLL | (2R,3R,4R,5R)-2-((1S,2S,3R,4S,6R)-4,6-DIAMINO-3-((2R,3R,6S)-3-AMINO-6-(AMINOMETHYL)-TETRAHYDRO-2H-PYRAN-2-YLOXY)-2-HYDROXYCYCLOHEXYLOXY)-5-METHYL-4-(METHYLAMINO)-TETRAHYDRO-2H-PYRAN-3,5-DIOL | 1 |
| M5Z | (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-4,6-O-[(1R)-3-phenylpropylidene]-alpha-D-glucopyranoside | 1 |
| ON0 | (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-4,6-O-benzylidene-2-deoxy-alpha-D-glucopyranoside | 1 |
| PUT | 1,4-DIAMINOBUTANE | 1 |
| RPO | (1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-4-O-benzyl-2-deoxy-alpha-D-glucopyranoside | 1 |
| TAC | TETRACYCLINE | 1 |